secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001104659-21-100444
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond appoints interim CMO and new CSO; CMO and CSO depart
------------------------------------------------------------------

- Karsten Witt appointed Interim CMO, effective Aug 4, 2021, succeeding Rachel Humphrey.
- Rachel Humphrey offered separation agreement with severance, advisory role until Feb 28, 2022; vested option extension.
- Elizabeth Buck appointed Chief Scientific Officer, effective Aug 11, 2021, succeeding Christopher Roberts.
- Christopher Roberts resigned to become CEO at another company; will serve as advisor post-departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/0001104659-21-100444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921100444/tm2123993d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer